Association of immune‐related pneumonitis with clinical benefit of anti‐programmed cell death‐1 monotherapy in advanced non‐small cell lung cancer
Kana Ono(Sendai Kousei Hospital), Shunichi Sugawara(Sendai Kousei Hospital), Shin Saito(Shizuoka Cancer Center), Tomoiki Aiba(Sendai Kousei Hospital), Keisuke Terayama(Sendai Kousei Hospital), Yosuke Kawashima(Sendai Kousei Hospital), Akane Narumi(Sendai Kousei Hospital), Yutaka Domeki(Sendai Kousei Hospital), Shinsuke Yamanda(Sendai Kousei Hospital), Suguru Matsuda(Sendai Kousei Hospital), Hirotaka Ono(Tsuyama Chuo Hospital), Mari Aso(Sendai Kousei Hospital), Tetsuo Odaka(Sendai Kousei Hospital), Takahiro Ogasawara(Sendai Kousei Hospital), Sachiko Kawana(Sendai Kousei Hospital), Yuichiro Kimura(Tohoku University), Yukihiro Toi(Sendai Kousei Hospital), Atsushi Nakamura(Sendai Kousei Hospital), Yoshihiro Honda, Hisashi Shimizu, Ryohei Saito(Sapporo Medical University), Jun Sugisaka(Sendai Kousei Hospital)
Cited by 19
Related Papers
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
|The Lancet|2021|1.5k
Osimertinib with or without Chemotherapy in <i>EGFR</i> -Mutated Advanced NSCLC
|New England Journal of Medicine|2023|695